http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020038491-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74b7b50944d8e1960440fb1f5440b7fd |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 |
filingDate | 2017-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adcfbfef2db982b3d8f731c8f018be98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8782948dbbee7044e445efebc4ebce8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cd10bb2779bbc593966bc8346ddae25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fdf53b11a88e14d98fc2626fd239f45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e446826a8b90ca9e7479ff15b92a609d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_487a90cb5da5f9b52f7aae418dff0179 |
publicationDate | 2020-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2020038491-A1 |
titleOfInvention | Methods for reducing liver fibrosis and treating lysosomal acid lipase deficiency in patients based on ishak fibrosis stage |
abstract | The present invention provides methods of reducing liver fibrosis in a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction (e.g., a ≥1 point reduction or a ≥2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration. Also provided are methods of treating a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction (e.g., a ≥1 point reduction or a ≥2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration. |
priorityDate | 2016-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 815.